U.S. and Canadian Transportation Security Officials Tour Implant Sciences' Headquarters Industry regulators gain insight into innovative new ETD technologies
WILMINGTON, Mass., March 5, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that officials from the United States Transportation Security Administration (TSA) and the Canadian Air Transport Security Authority (CATSA) toured Implant Sciences' headquarters and 58,000 sq. ft. manufacturing facility in Wilmington, Massachusetts on Tuesday, January 28, 2014.
TSA and CATSA work together in a partnership to explore existing and new technologies. During the tour, officials met with Implant Sciences' executives and staff and learned about the manufacturing processes of the QS-B220 and QS-H150 explosives trace detectors (ETD), which are currently used around the world in mission critical security applications. The Company also provided updates on new ETD technologies being developed for future applications.
Implant Sciences President and CEO, Glenn Bolduc, commented, "We were pleased to have the opportunity to host officials from the TSA and CATSA. These agencies play a critical role in keeping passengers and aviation facilities safe. This visit was an opportunity to demonstrate to some of the biggest security equipment procurers in the world that Implant Sciences is a small business that can deliver quality security technology. We trust that they were impressed by our state-of-the-art manufacturing facility and by the caliber of our personnel."
The Company's QS-B220 desktop ETD has received TSA qualification for air cargo screening and is currently is in the final stages of TSA qualification for checkpoint and checked baggage screening.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation